TY  - GEN
AU  - Vlasveld,L T
AU  - Hekman,A
AU  - Vyth-Dreese,F A
AU  - Melief,C J
AU  - Sein,J J
AU  - Voordouw,A C
AU  - Dellemijn,T A
AU  - Rankin,E M
TI  - Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19
SN  - 0340-7004
PY  - 1995///0223
KW  - Adult
KW  - Aged
KW  - Animals
KW  - Antibodies, Monoclonal
KW  - adverse effects
KW  - Antigen-Antibody Reactions
KW  - Antigens, CD
KW  - immunology
KW  - Antigens, CD19
KW  - Antigens, Differentiation, B-Lymphocyte
KW  - B-Lymphocytes
KW  - Combined Modality Therapy
KW  - Complement System Proteins
KW  - metabolism
KW  - Cytotoxicity, Immunologic
KW  - Dose-Response Relationship, Immunologic
KW  - Female
KW  - Humans
KW  - Immunoglobulins
KW  - blood
KW  - Immunophenotyping
KW  - Infusions, Intravenous
KW  - Interleukin-2
KW  - Leukocyte Count
KW  - Lymphocyte Activation
KW  - Lymphoma, Non-Hodgkin
KW  - Male
KW  - Mice
KW  - Middle Aged
KW  - Receptors, Interleukin-2
KW  - Recombinant Proteins
KW  - therapeutic use
KW  - T-Lymphocytes
N1  - Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/BF01517234
ER  -